FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313413337> ?p ?o ?g. }

• W2313413337 abstract "Fms-like tyrosine kinase 3 (FLT3) is thought to be a major driver in the pathogenesis of acute myeloid leukemia (AML). FLT3-activating mutations are found in ∼ 30% of AML patients and are associated with poor outcome in this patient population. AC220 is a small molecule kinase inhibitor with potent and selective FLT3 inhibitory activity. Here we characterize the effect of AC220 on FLT3 autophosphorylation, activation of downstream signaling pathways (STAT5, ERK and AKT), cell cycle distribution, and apoptosis endpoints in multiple leukemia cell lines expressing either wild type FLT3 (FLT3-WT, SEM-K2 cells (FLT3-WT overexpression) and RS4;11 cells (FLT3-WT)) and/or ITD-mutated FLT3 (FLT3-ITD, MV4-11 (FLT3-ITD), MOLM-14 (FLT3-ITD/FLT3-WT)). Across each of these parameters we also compare the effects of AC220 to those of other known FLT3 inhibitors including, sorafenib, sunitinib, lestaurtinib, and midostaurin. AC220 inhibited FLT3 autophosphorylation in both FLT3-WT and FLT3-ITD cells with roughly equal potency, while other FLT3 inhibitors showed differential pFLT3 inhibition across several cell lines. Although AC220-mediated inhibition of FLT3 autophosphorylation was observed in all cell lines, subsequent cell death was only detected in the cell lines with activated FLT3. This contrasts with other FLT3 inhibitors, where potent inhibition of cell proliferation in the non-FLT3 activated RS4;11 cells was observed, highlighting the lack of FLT3 selectivity of these compounds. Consistent with FLT3 inhibition, AC220 also inhibited constitutively activated STAT5, ERK and AKT in these cell lines, suggesting that one or more of these pathways play a role in FLT3-mediated cell growth and survival. Furthermore, the inhibition of these downstream markers correlated with the inhibition of FLT3 across each of the FLT3 inhibitors tested. Lastly, in an MV4-11 murine xenograft model, AC220 administration resulted in the reduction of phosphorylated FLT3 and downstream signaling molecules concomitant with tumor reduction. Together, these data suggest that selective FLT3 inhibition is sufficient to inhibit the growth and induce cell death of FLT3-driven leukemia cells. AC220 is currently being evaluated in a phase II clinical trials in relapsed or refractory AML patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3619." @default.
• W2313413337 created "2016-06-24" @default.
• W2313413337 creator A5003086261 @default.
• W2313413337 creator A5015710627 @default.
• W2313413337 creator A5016471133 @default.
• W2313413337 creator A5028958964 @default.
• W2313413337 creator A5029530376 @default.
• W2313413337 creator A5070304479 @default.
• W2313413337 creator A5074362691 @default.
• W2313413337 creator A5076486233 @default.
• W2313413337 creator A5079653527 @default.
• W2313413337 creator A5087085239 @default.
• W2313413337 date "2010-04-15" @default.
• W2313413337 modified "2023-09-25" @default.
• W2313413337 title "Abstract 3619: Inhibition of FLT3 autophosphorylation and downstream signaling both in vitro and in vivo by AC220, a second generation potent and selective FLT3 inhibitor" @default.
• W2313413337 doi "https://doi.org/10.1158/1538-7445.am10-3619" @default.
• W2313413337 hasPublicationYear "2010" @default.
• W2313413337 type Work @default.
• W2313413337 sameAs 2313413337 @default.
• W2313413337 citedByCount "0" @default.
• W2313413337 crossrefType "proceedings-article" @default.
• W2313413337 hasAuthorship W2313413337A5003086261 @default.
• W2313413337 hasAuthorship W2313413337A5015710627 @default.
• W2313413337 hasAuthorship W2313413337A5016471133 @default.
• W2313413337 hasAuthorship W2313413337A5028958964 @default.
• W2313413337 hasAuthorship W2313413337A5029530376 @default.
• W2313413337 hasAuthorship W2313413337A5070304479 @default.
• W2313413337 hasAuthorship W2313413337A5074362691 @default.
• W2313413337 hasAuthorship W2313413337A5076486233 @default.
• W2313413337 hasAuthorship W2313413337A5079653527 @default.
• W2313413337 hasAuthorship W2313413337A5087085239 @default.
• W2313413337 hasConcept C104317684 @default.
• W2313413337 hasConcept C11960822 @default.
• W2313413337 hasConcept C150109051 @default.
• W2313413337 hasConcept C153911025 @default.
• W2313413337 hasConcept C184235292 @default.
• W2313413337 hasConcept C185592680 @default.
• W2313413337 hasConcept C2776481607 @default.
• W2313413337 hasConcept C2778019345 @default.
• W2313413337 hasConcept C2778695046 @default.
• W2313413337 hasConcept C2778729363 @default.
• W2313413337 hasConcept C2908647359 @default.
• W2313413337 hasConcept C2910954276 @default.
• W2313413337 hasConcept C501734568 @default.
• W2313413337 hasConcept C502942594 @default.
• W2313413337 hasConcept C54355233 @default.
• W2313413337 hasConcept C55493867 @default.
• W2313413337 hasConcept C71924100 @default.
• W2313413337 hasConcept C75217442 @default.
• W2313413337 hasConcept C81885089 @default.
• W2313413337 hasConcept C86803240 @default.
• W2313413337 hasConcept C95444343 @default.
• W2313413337 hasConcept C97029542 @default.
• W2313413337 hasConcept C98274493 @default.
• W2313413337 hasConcept C99454951 @default.
• W2313413337 hasConceptScore W2313413337C104317684 @default.
• W2313413337 hasConceptScore W2313413337C11960822 @default.
• W2313413337 hasConceptScore W2313413337C150109051 @default.
• W2313413337 hasConceptScore W2313413337C153911025 @default.
• W2313413337 hasConceptScore W2313413337C184235292 @default.
• W2313413337 hasConceptScore W2313413337C185592680 @default.
• W2313413337 hasConceptScore W2313413337C2776481607 @default.
• W2313413337 hasConceptScore W2313413337C2778019345 @default.
• W2313413337 hasConceptScore W2313413337C2778695046 @default.
• W2313413337 hasConceptScore W2313413337C2778729363 @default.
• W2313413337 hasConceptScore W2313413337C2908647359 @default.
• W2313413337 hasConceptScore W2313413337C2910954276 @default.
• W2313413337 hasConceptScore W2313413337C501734568 @default.
• W2313413337 hasConceptScore W2313413337C502942594 @default.
• W2313413337 hasConceptScore W2313413337C54355233 @default.
• W2313413337 hasConceptScore W2313413337C55493867 @default.
• W2313413337 hasConceptScore W2313413337C71924100 @default.
• W2313413337 hasConceptScore W2313413337C75217442 @default.
• W2313413337 hasConceptScore W2313413337C81885089 @default.
• W2313413337 hasConceptScore W2313413337C86803240 @default.
• W2313413337 hasConceptScore W2313413337C95444343 @default.
• W2313413337 hasConceptScore W2313413337C97029542 @default.
• W2313413337 hasConceptScore W2313413337C98274493 @default.
• W2313413337 hasConceptScore W2313413337C99454951 @default.
• W2313413337 hasLocation W23134133371 @default.
• W2313413337 hasOpenAccess W2313413337 @default.
• W2313413337 hasPrimaryLocation W23134133371 @default.
• W2313413337 hasRelatedWork W1541434165 @default.
• W2313413337 hasRelatedWork W1559155312 @default.
• W2313413337 hasRelatedWork W1980936615 @default.
• W2313413337 hasRelatedWork W2502155032 @default.
• W2313413337 hasRelatedWork W2550086308 @default.
• W2313413337 hasRelatedWork W2559072271 @default.
• W2313413337 hasRelatedWork W2586694074 @default.
• W2313413337 hasRelatedWork W2589176952 @default.
• W2313413337 hasRelatedWork W2741093390 @default.
• W2313413337 hasRelatedWork W2767156284 @default.
• W2313413337 hasRelatedWork W2793050879 @default.
• W2313413337 hasRelatedWork W2887815924 @default.
• W2313413337 hasRelatedWork W2890395182 @default.
• W2313413337 hasRelatedWork W2979759945 @default.
• W2313413337 hasRelatedWork W2979958239 @default.
• W2313413337 hasRelatedWork W2980036978 @default.
• W2313413337 hasRelatedWork W2981225460 @default.
• W2313413337 hasRelatedWork W2981367742 @default.

• next